Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766543 · ClinicalTrials.gov registry record · NA
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
A NA study of Prostate Cancer, sponsored by Profound Medical.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 14
- Study locations
NCT02766543: Active NA study of Prostate Cancer, sponsored by Profound Medical.
NCT02766543 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Profound Medical. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02766543, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Profound Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 14
- Study locations
Study Summary
A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
Primary Outcome
Frequency and severity of all adverse events will be evaluated by attribution and reported in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) standard published by the National Cancer Institute (NCI).
Conditions Studied
Interventions
- DEVICE MRI-guided Transurethral Ultrasound Ablation
Study Locations (14)
Other
- University Hospital of Cologne - Cologne
- Universitätsklinikum Heidelberg (University of Heidelberg, Dept of Urology) - Heidelberg
- Radboud University Medical Center - Nijmegen
- ResoFus Alomar (Hospital Universitari De Bellvitge) - Barcelona
Ontario
- London Health Sciences Centre - London
- Sunnybrook Health Sciences Centre - Toronto
California
- University of California Los Angeles - Los Angeles
Connecticut
- Yale Cancer Centre - New Haven
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Maryland
- Johns Hopkins Medicine - Baltimore
Michigan
- William Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2028-09-30 |
| Phase | NA |
What the registry record for NCT02766543 still lists
NCT02766543 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI-guided Transurethral Ultrasound Ablation is the first listed.
NCT02766543 lists 14 locations in 10 states (Other, Ontario, California).
Frequently Asked Questions
What is clinical trial NCT02766543 about?
NCT02766543 is a clinical study titled "Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer". A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients wi...
What is the current status of trial NCT02766543?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2016-09-21. Estimated completion is 2028-09-30.
What conditions does trial NCT02766543 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02766543?
The interventions under investigation include: MRI-guided Transurethral Ultrasound Ablation (DEVICE).
Who is sponsoring clinical trial NCT02766543?
This trial is sponsored by Profound Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02766543 being conducted?
This trial has 14 study locations across California, Connecticut, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02766543's enrollment target sits among peer trials
150 260th of 735 higher than 464 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02455479 · 150 participants · Phase 1
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI